Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
Open Access
Abstract
Objective Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options. However, metabolic adaptation to the harsh PDAC environment can expose liabilities useful for therapy. Targeting the key metabolic regulator mechanistic target of rapamycin complex 1 (mTORC1) and its downstream pathway shows efficacy only in subsets of patients but gene modifiers maximising response remain to be identified. Design Three independent cohorts of PDAC patients were studied to correlate PI3K-C2γ protein abundance with disease outcome. Mechanisms were then studied in mouse (KPC mice) and cellular models of PDAC, in presence or absence of PI3K-C2γ (WT or KO). PI3K-C2γ-dependent metabolic rewiring and its impact on mTORC1 regulation were assessed in conditions of limiting glutamine availability. Finally, effects of a combination therapy targeting mTORC1 and glutamine metabolism were studied in WT and KO PDAC cells and preclinical models. Results PI3K-C2γ expression was reduced in about 30% of PDAC cases and was associated with an aggressive phenotype. Similarly, loss of PI3K-C2γ in KPC mice enhanced tumour development and progression. The increased aggressiveness of tumours lacking PI3K-C2γ correlated with hyperactivation of mTORC1 pathway and glutamine metabolism rewiring to support lipid synthesis. PI3K-C2γ-KO tumours failed to adapt to metabolic stress induced by glutamine depletion, resulting in cell death. Conclusion Loss of PI3K-C2γ prevents mTOR inactivation and triggers tumour vulnerability to RAD001 (mTOR inhibitor) and BPTES/CB-839 (glutaminase inhibitors). Therefore, these results might open the way to personalised treatments in PDAC with PI3K-C2γ loss.Keywords
Funding Information
- Worldwide Cancer Research (20-0033)
- Fondazione Pezcoller (Not applicable)
- Ministero della Salute (FIMPDACUP_J38D19000690001)
- KWF Kankerbestrijding (KWF-11957)
- Network of Excellence (19CVD02)
- Associazione Italiana per la Ricerca sul Cancro (12182)
- Associazione Italiana per la Ricerca sul Cancro (18718)
- Associazione Italiana per la Ricerca sul Cancro (21875)
- Associazione Italiana per la Ricerca sul Cancro (22248)
- Associazione Italiana per la Ricerca sul Cancro (22558)
- Associazione Italiana per la Ricerca sul Cancro (IG24444)
- Associazione Italiana per la Ricerca sul Cancro (MFAG 2018)
This publication has 45 references indexed in Scilit:
- RETRACTED: The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc TranslationCurrent Biology, 2014
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathwayNature, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysisBiochemical Journal, 2011
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancerOncogene, 2009
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic CancerJournal of Clinical Oncology, 2009
- Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and RecommendationsCancer Research, 2006
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- Phosphoinositide-dependent Activation of the ADP-ribosylation Factor GTPase-activating Protein ASAP1Journal of Biological Chemistry, 2000